The present study has addressed the following questions: 1) whether cholesterol-lowering by any means affects HDAC activity and chromatin modifications of fibrotic and anti-fibrotic genes in the diabetic kidney and, 2) if treatment with a specific statin confers any additional renal benefits beyond its cholesterol-lowering action in rats with diabetes (DM). This evidence concerns the gene HDAC9 and diabetes mellitus.